NCT02699099View on ClinicalTrials.gov

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

PHASE3CompletedINTERVENTIONAL
Enrollment

699

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

March 14, 2018

Study Completion Date

October 7, 2020

Conditions
MalariaMalaria Vaccines
Interventions
DIETARY_SUPPLEMENT

Vitamin A

Oral administration of Vitamin A (1 dose)

BIOLOGICAL

Candidate Plasmodium falciparum malaria vaccine

Intramuscular administration of SB257049 vaccine (4 doses)

BIOLOGICAL

MR-Vac

Subcutaneous injection of a combined measles and rubella vaccine (1 dose)

BIOLOGICAL

Stamaril

Intramuscular injection of a yellow fever (YF) vaccine (1 dose)

Trial Locations (2)

Unknown

GSK Investigational Site, Kintampo

GSK Investigational Site, Kumasi

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02699099 - Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. | Biotech Hunter | Biotech Hunter